Membranous glomerulonephritis laboratory findings

Membranous glomerulonephritis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Membranous glomerulonephritis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
CT
Ultrasound
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Membranous glomerulonephritis laboratory findings On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Membranous glomerulonephritis laboratory findings All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Membranous glomerulonephritis laboratory findings
CDC on Membranous glomerulonephritis laboratory findings
Membranous glomerulonephritis laboratory findings in the news
Blogs on Membranous glomerulonephritis laboratory findings
Directions to Hospitals Treating Membranous glomerulonephritis
Risk calculators and risk factors for Membranous glomerulonephritis laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Syed Ahsan Hussain, M.D.[2]

Laboratory Findings

• Comprehensive chemistry panel including serum albumin
• Complete blood count
• Urinalysis with examination of the sediment
• 24-hour urine collection for protein quantification and creatinine clearance
• ANA and, if positive, anti-double-stranded DNA (anti-dsDNA), anti-Sm, anti-Ro/SSA, and anti-La/SSB antibodies
• Tests for hepatitis B and C viruses and the human immunodeficiency virus (HIV) (see "Hepatitis B virus: Screening and diagnosis", section on 'Diagnostic algorithms' and "Diagnosis and evaluation of chronic hepatitis C virus infection", section on 'Testing algorithm' and "Screening and diagnostic testing for HIV infection", section on 'Testing algorithm')
• Serum C3 and C4 complement levels
• In patients older than 50 years – serum free light chains (SFLCs) and serum protein electrophoresis (SPEP) with immunofixation
• Chest radiograph (or computed tomography [CT] of the chest in patients with a history of smoking or asbestos exposure)
• Anti-PLA2R antibody (by enzyme-linked immunosorbent assay [ELISA])